Author:
Chisholm Dan,Sanderson Kristy,Ayuso-Mateos Jose Luis,Saxena Shekhar
Abstract
BackgroundInternational evidence on the cost and effects of interventions for reducing the global burden of depression remain scarce.AimsTo estimate the population-level cost-effectiveness of evidence-based depression interventions and their contribution towards reducing current burden.MethodPrimary-care-based depression interventions were modelled at the level of whole populations in 14 epidemiological subregions of the world. Total population-level costs (in international dollars or I) and effectiveness (disability adjusted life years (DALYs) averted) were combined to form average and incremental cost-effectiveness ratios.ResultsEvaluated interventions have the potential to reduce the current burden of depression by 10–30%. Pharmacotherapy with older antidepressant drugs, with or without proactive collaborative care, are currently more cost-effective strategies than those using newer antidepressants, particularly in lower-income subregions.ConclusionsEven in resource-poor regions, each DALYaverted by efficient depression treatments in primary care costs less than 1 year of average per capita income, making such interventions a cost-effective use of health resources. However, current levels of burden can only be reduced significantly if there is a substantial increase in treatment coverage.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
272 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献